A cohort of 4000 community-dwelling adults is followed to evaluate the effectiveness of the Finnish national A(H1N1)v influenza vaccination campaign in preventing the first episode of laboratory-confirmed A(H1N1)v influenza. The safety of vaccination and the severity of the disease are followed primarily from health care registers. In a subgroup of 200 participants, the humoral and cellular immunogenicity of the vaccine will be studied.
Study Type
OBSERVATIONAL
Enrollment
3,518
Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
National Institute for Health and Welfare
Tampere, Finland
Effectiveness of vaccination in preventing the first episode of laboratory-confirmed A(H1N1)v infection in adults
Time frame: 3 November 2009 to 30 April 2010
Safety of vaccination with the A(H1N1)v vaccine
Time frame: 3 November 2009 to 31 October-November 2010
Severity and possible complications of the A(H1N1)v influenza
Time frame: 3 November 2009 to 31 October-November 2010
Humoral and cellular immune responses to the vaccine (subgroup of 200 adults)
Time frame: 3 November 2009 to 31 October-November 2010
Effectiveness of the vaccine in subgroups
Time frame: 3 November 2009 to 31 October-November 2010
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.